JENA, Germany – February 26, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm at the forefront of developing anti-inflammatory treatments by targeting the complement system, today announced its participation in the Leerink Partners Global Healthcare Conference. Key details are as follows:
Leerink Partners Global Healthcare Conference
March 8 – 11, 2026 in Miami, FL
Fireside chat on March 9 at 9:20 AM ET
InflaRx will also host one-on-one investor meetings on March 9. A link to view the live stream of the fireside chat and its replay is available.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company leading the way in anti-inflammatory therapies, leveraging its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide range of inflammatory diseases. InflaRx’s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics and therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory conditions, including hidradenitis suppurativa (HS). InflaRx has also developed vilobelimab, a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability across multiple clinical studies.
InflaRx was founded in 2007, with offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For additional information, please visit [website]. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively referred to as InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than those based on historical fact are forward-looking, often identified by terms like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among others. Forward-looking statements appear throughout this release and may include comments on our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors outlined under the headings “Risk factors” and “Cautionary statement regarding forward-looking statements” in our periodic filings with the SEC. These statements are valid only as of the date of this press release and involve known and unknown risks, uncertainties, and other key factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update them in the future—even if new information becomes available—except as required by law.
